• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by MEI Pharma Inc.

    12/20/24 5:15:02 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MEIP alert in real time by email
    DEFA14A 1 2025_defa_14a_notice__ac.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material Pursuant to § 240.14a-12

    MEI PHARMA, INC.

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     


     

     

    img243975296_0.jpg

    www.investorvote.com/MEIP Step 1: Go to www.investorvote.com/MEIP. Step 2: Click on the icon on the right to view meeting materials. Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in. Online Go to www.investorvote.com/MEIP or scan the QR code — login details are located in the shaded bar below. Stockholder Meeting Notice 042QXC Important Notice Regarding the Availability of Proxy Materials for the MEI Pharma, Inc. Stockholder Meeting to be Held on January 30, 2025 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement and annual report to stockholders are available at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before January 15, 2025 to facilitate timely delivery. 2 N O T Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares.

     

     


     

     

    img243975296_1.jpg

    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.investorvote.com/MEIP. — P hone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials MEI Pharma, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, requests for a paper copy of proxy materials must be received by January 15, 2025. MEI Pharma, Inc.’s Annual Meeting of Stockholders will be held on January 30, 2025, at 9:00 a.m. Pacific Time, virtually via the Internet at meetnow.global/MFTTW6U. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommends a vote FOR all the nominees listed and FOR Proposals 2 and 3: 1. To elect two directors to our Board of Directors, to serve until the expiration of their terms in fiscal year 2028 and until their successor is elected and qualified. 01 - Frederick W. Driscoll 02 - Nicholas R. Glover, Ph.D 2. To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement. 3. To ratify the appointment of Deloitte & Touche LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending June 30, 2025. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you. Stockholder Meeting Notice

     

     


    Get the next $MEIP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MEIP

    DatePrice TargetRatingAnalyst
    7/23/2024Buy → Hold
    Laidlaw
    3/25/2022$4.00 → $1.00Buy → Hold
    Jefferies
    3/25/2022$13.00 → $2.00Overweight → Equal Weight
    Wells Fargo
    3/25/2022$6.00 → $2.00Buy → Hold
    Stifel
    2/3/2022$4.00Buy
    Jefferies
    More analyst ratings

    $MEIP
    SEC Filings

    View All

    MEI Pharma Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - Lite Strategy, Inc. (0001262104) (Filer)

    9/15/25 4:00:26 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MEI Pharma, Inc. (0001262104) (Filer)

    9/10/25 9:00:27 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by MEI Pharma Inc.

    EFFECT - MEI Pharma, Inc. (0001262104) (Filer)

    9/8/25 12:15:11 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MEIP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker 'LITS'

    Lite Strategy Rebrand Aligns with Company's LTC Digital Asset Treasury Strategy Advised by GSR Ventures MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI" or the "Company") today announced that it will change its corporate name to Lite Strategy, Inc., reflecting the Company's expansion into a pioneer in digital asset treasury management. Alongside the rebrand, the Company's ticker symbol on the NASDAQ Stock Market will transition from MEIP to LITS, effective at market open on September 11, 2025. The rebranding to Lite Strategy, Inc. underscores the Company's commitment to building a long-term corporate strategy around Litecoin (LTC) as our primary reserve asset. In August, MEI became the first U.S.-

    9/10/25 9:00:00 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

    MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI" or "the Company") today announced the acquisition of 929,548 Litecoin (LTC) tokens at an average price of $107.58, successfully launching a major institutional treasury strategy with the LTC treasury now valued at approximately $110.4 million as of August 4, 2025. MEI becomes the first U.S.-listed public company to adopt Litecoin as a primary reserve asset, implementing a new strategy built on digital asset infrastructure and long-term capital innovation. This strategic move, developed in partnership with GSR and with guidance provided by Litecoin Creator and MEI Board member Charlie Lee, marks the beginning of MEI's broader institutional treasury ini

    8/5/25 8:00:00 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

    Charlie Lee, the Founder of Litecoin and a lead investor in the PIPE, has joined the Board of Directors of the Company GSR, a preeminent digital asset market maker and lead investor in the private placement, has been appointed to act as the treasury's Asset Manager MEI Pharma will use 100% of the net proceeds to launch its treasury strategy focused on Litecoin, becoming the first and only publicly traded LTC holder on a national exchange MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company" or "MEI") today announced that it has closed its previously announced private placement for the purchase and sale of 29,239,767 shares of common stock (or pre-funded warrants in lieu thereof) at a pric

    7/22/25 4:35:00 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MEIP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    MEI Pharma downgraded by Laidlaw

    Laidlaw downgraded MEI Pharma from Buy to Hold

    7/23/24 6:35:29 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma downgraded by Jefferies with a new price target

    Jefferies downgraded MEI Pharma from Buy to Hold and set a new price target of $1.00 from $4.00 previously

    3/25/22 7:17:08 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded MEI Pharma from Overweight to Equal Weight and set a new price target of $2.00 from $13.00 previously

    3/25/22 7:16:36 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MEIP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Schornstein Alexander claimed ownership of 4,365,472 shares (SEC Form 3)

    3 - Lite Strategy, Inc. (0001262104) (Issuer)

    9/10/25 4:40:54 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Riezman Joshua

    4 - MEI Pharma, Inc. (0001262104) (Issuer)

    8/20/25 5:56:34 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Riezman Joshua

    3 - MEI Pharma, Inc. (0001262104) (Issuer)

    8/20/25 5:54:23 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MEIP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Anson Funds Management Lp bought $329,331 worth of shares (48,060 units at $6.85) (SEC Form 4)

    4 - MEI Pharma, Inc. (0001262104) (Issuer)

    9/25/23 7:43:12 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Funicular Funds, Lp bought $219,554 worth of shares (32,040 units at $6.85) (SEC Form 4)

    4 - MEI Pharma, Inc. (0001262104) (Issuer)

    9/25/23 7:41:22 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Anson Funds Management Lp bought $938,226 worth of shares (153,600 units at $6.11)

    4 - MEI Pharma, Inc. (0001262104) (Issuer)

    9/22/23 9:21:02 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MEIP
    Leadership Updates

    Live Leadership Updates

    View All

    MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor

    MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, consistent with the Company's succession planning, Brian Drazba's tenure as Chief Financial Officer of the Company will end no later than September 1, 2023, and the Company has hired Justin (Jay) File as his successor. Mr. File joined the Company on June 12, 2023 as Executive Vice President, Finance and will be appointed Chief Financial Officer upon Mr. Drazba's departure. "Brian has been a true asset to MEI providing invaluable fiscal and business leadership as we advanced our clinical programs and executed various transactions, incl

    6/13/23 8:00:00 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor

    MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, in connection with the Company's previously announced succession plan, Daniel P. Gold, Ph.D's tenure as the president and chief executive officer of MEI will end on June 2, 2023 and the Company's board of directors has appointed David M. Urso as his successor. Mr. Urso, who joined the Company in 2014 and has been serving as the company's chief operating officer since 2018, will also join the board of directors. Dr. Gold will remain on MEI's board, where he will continue to share his extensive knowledge and experience with the company.

    6/2/23 8:00:00 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer

    MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Anne Frese, an experienced industry executive, joined MEI as chief people officer, a role reporting to Daniel P. Gold, chief executive officer. Ms. Frese will be responsible for the strategy and processes related to building and retaining an exceptional team of professionals. Ms. Frese's appointment is effective immediately. Ms. Frese joins MEI with over 30 years of human resource experience across a variety of industries, including biotech, consulting, hospitality, and engineering. Most recently, she served as chief human resources officer at Vyripharm En

    6/22/22 8:00:00 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MEIP
    Financials

    Live finance-specific insights

    View All

    MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

    MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI" or "the Company") today announced the acquisition of 929,548 Litecoin (LTC) tokens at an average price of $107.58, successfully launching a major institutional treasury strategy with the LTC treasury now valued at approximately $110.4 million as of August 4, 2025. MEI becomes the first U.S.-listed public company to adopt Litecoin as a primary reserve asset, implementing a new strategy built on digital asset infrastructure and long-term capital innovation. This strategic move, developed in partnership with GSR and with guidance provided by Litecoin Creator and MEI Board member Charlie Lee, marks the beginning of MEI's broader institutional treasury ini

    8/5/25 8:00:00 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

    Evaluation of Strategic Alternatives is Ongoing MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first half of fiscal year 2025, the Company commenced c

    2/12/25 4:12:00 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

    Reaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first quarter of fiscal year 2025, the Company comme

    11/12/24 4:05:00 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MEIP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by MEI Pharma Inc. (Amendment)

    SC 13G/A - MEI Pharma, Inc. (0001262104) (Subject)

    2/14/24 4:00:25 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by MEI Pharma Inc. (Amendment)

    SC 13G/A - MEI Pharma, Inc. (0001262104) (Subject)

    2/13/24 5:09:37 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by MEI Pharma Inc. (Amendment)

    SC 13D/A - MEI Pharma, Inc. (0001262104) (Subject)

    11/1/23 5:20:11 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care